MA39427A1 - Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète - Google Patents
Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabèteInfo
- Publication number
- MA39427A1 MA39427A1 MA39427A MA39427A MA39427A1 MA 39427 A1 MA39427 A1 MA 39427A1 MA 39427 A MA39427 A MA 39427A MA 39427 A MA39427 A MA 39427A MA 39427 A1 MA39427 A1 MA 39427A1
- Authority
- MA
- Morocco
- Prior art keywords
- gpr40
- pyrrolidine
- diabetes
- diseases
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (i) ou un stéréo-isomère, un tautomère, un sel pharmaceutiquement acceptable, un polymorphe ou un solvate desdits composés, toutes les variables de la formule étant telles que définies dans la description. Ces composés sont des modulateurs du récepteur couplé aux protéines g gpr40, qui peuvent être utilisés en tant que médicaments.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461989651P | 2014-05-07 | 2014-05-07 | |
PCT/US2015/029409 WO2015171722A1 (fr) | 2014-05-07 | 2015-05-06 | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39427A1 true MA39427A1 (fr) | 2017-11-30 |
MA39427B1 MA39427B1 (fr) | 2018-09-28 |
Family
ID=53181359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39427A MA39427B1 (fr) | 2014-05-07 | 2015-05-06 | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète |
Country Status (32)
Country | Link |
---|---|
US (4) | US9873679B2 (fr) |
EP (1) | EP3140296B1 (fr) |
JP (1) | JP6483156B2 (fr) |
KR (1) | KR102336370B1 (fr) |
CN (1) | CN106458976B (fr) |
AR (1) | AR100328A1 (fr) |
AU (1) | AU2015256120B2 (fr) |
BR (1) | BR112016024936A2 (fr) |
CA (1) | CA2948161C (fr) |
CL (1) | CL2016002809A1 (fr) |
CY (1) | CY1120340T1 (fr) |
DK (1) | DK3140296T3 (fr) |
EA (1) | EA033250B1 (fr) |
ES (1) | ES2674531T3 (fr) |
HR (1) | HRP20180641T1 (fr) |
HU (1) | HUE039288T2 (fr) |
IL (1) | IL248668B (fr) |
MA (1) | MA39427B1 (fr) |
MX (1) | MX2016013801A (fr) |
MY (1) | MY181959A (fr) |
NZ (1) | NZ727146A (fr) |
PE (1) | PE20161363A1 (fr) |
PH (1) | PH12016502034B1 (fr) |
PL (1) | PL3140296T3 (fr) |
PT (1) | PT3140296T (fr) |
RS (1) | RS57170B1 (fr) |
SG (1) | SG11201609170UA (fr) |
SI (1) | SI3140296T1 (fr) |
TN (1) | TN2016000444A1 (fr) |
TR (1) | TR201809633T4 (fr) |
TW (1) | TWI659951B (fr) |
WO (1) | WO2015171722A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY181959A (en) * | 2014-05-07 | 2021-01-15 | Bristol Myers Squibb Co | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
EP3140297B1 (fr) * | 2014-05-07 | 2018-04-11 | Bristol-Myers Squibb Company | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète |
CA3041038A1 (fr) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Composes bicycliques utiles en tant que modulateurs du gpr120 |
US10800773B2 (en) | 2016-09-12 | 2020-10-13 | Integral Health, Inc. | Monocyclic compounds useful as GPR120 modulators |
JPWO2018181847A1 (ja) * | 2017-03-31 | 2020-03-05 | 武田薬品工業株式会社 | 芳香環化合物 |
CN110772636B (zh) * | 2017-08-21 | 2021-03-16 | 武汉大学 | Gpr31抑制剂在制备治疗心脏缺血再灌注损伤及相关疾病药物中的应用 |
IL300572A (en) | 2018-02-13 | 2023-04-01 | Gilead Sciences Inc | PD–1/PD–L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2020113094A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composés pyrrole et pyrazole et leurs procédés d'utilisation |
IL308122A (en) | 2021-06-16 | 2023-12-01 | Celgene Corp | Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
AU2010303670A1 (en) * | 2009-10-06 | 2012-03-29 | Bristol-Myers Squibb Company | Pyrrolidine GPR40 modulators |
US7939569B1 (en) * | 2009-12-01 | 2011-05-10 | Hoffmann-La Roche Inc. | Aniline analogs as glycogen synthase activators |
GB2498976A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
US9120798B2 (en) | 2012-08-01 | 2015-09-01 | Bristol-Myers Squibb Company | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor |
JP6322203B2 (ja) | 2012-11-16 | 2018-05-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ジヒドロピラゾールgpr40モジュレーター |
US9604964B2 (en) | 2012-11-16 | 2017-03-28 | Bristol-Myers Squibb Company | Dihydropyrazole GPR40 modulators |
CA2891535A1 (fr) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Modulateurs dihydropyrazoles de gpr40 |
ES2606197T3 (es) * | 2012-11-16 | 2017-03-23 | Bristol-Myers Squibb Company | Moduladores pirrolidina de GPR40 |
MA39767B1 (fr) | 2014-05-07 | 2019-10-31 | Croma Pharma Ges M B H | Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec |
MY181959A (en) * | 2014-05-07 | 2021-01-15 | Bristol Myers Squibb Co | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
EP3140294A1 (fr) | 2014-05-07 | 2017-03-15 | Bristol-Myers Squibb Company | Modulateurs de gpr40 à base de pyrrolidine |
-
2015
- 2015-05-06 MY MYPI2016704054A patent/MY181959A/en unknown
- 2015-05-06 AR ARP150101379A patent/AR100328A1/es unknown
- 2015-05-06 CA CA2948161A patent/CA2948161C/fr active Active
- 2015-05-06 TW TW104114493A patent/TWI659951B/zh active
- 2015-05-06 HU HUE15723095A patent/HUE039288T2/hu unknown
- 2015-05-06 TN TN2016000444A patent/TN2016000444A1/en unknown
- 2015-05-06 WO PCT/US2015/029409 patent/WO2015171722A1/fr active Application Filing
- 2015-05-06 MA MA39427A patent/MA39427B1/fr unknown
- 2015-05-06 AU AU2015256120A patent/AU2015256120B2/en active Active
- 2015-05-06 TR TR2018/09633T patent/TR201809633T4/tr unknown
- 2015-05-06 PT PT157230954T patent/PT3140296T/pt unknown
- 2015-05-06 US US14/705,524 patent/US9873679B2/en active Active
- 2015-05-06 JP JP2016566651A patent/JP6483156B2/ja active Active
- 2015-05-06 RS RS20180504A patent/RS57170B1/sr unknown
- 2015-05-06 CN CN201580022579.4A patent/CN106458976B/zh active Active
- 2015-05-06 DK DK15723095.4T patent/DK3140296T3/en active
- 2015-05-06 EP EP15723095.4A patent/EP3140296B1/fr active Active
- 2015-05-06 BR BR112016024936A patent/BR112016024936A2/pt not_active Application Discontinuation
- 2015-05-06 KR KR1020167033863A patent/KR102336370B1/ko active IP Right Grant
- 2015-05-06 EA EA201692037A patent/EA033250B1/ru not_active IP Right Cessation
- 2015-05-06 PE PE2016002178A patent/PE20161363A1/es unknown
- 2015-05-06 SG SG11201609170UA patent/SG11201609170UA/en unknown
- 2015-05-06 ES ES15723095.4T patent/ES2674531T3/es active Active
- 2015-05-06 NZ NZ727146A patent/NZ727146A/en unknown
- 2015-05-06 PL PL15723095T patent/PL3140296T3/pl unknown
- 2015-05-06 MX MX2016013801A patent/MX2016013801A/es unknown
- 2015-05-06 SI SI201530232T patent/SI3140296T1/en unknown
-
2016
- 2016-10-12 PH PH12016502034A patent/PH12016502034B1/en unknown
- 2016-11-01 IL IL248668A patent/IL248668B/en active IP Right Grant
- 2016-11-07 CL CL2016002809A patent/CL2016002809A1/es unknown
-
2017
- 2017-12-13 US US15/840,198 patent/US20180099949A1/en not_active Abandoned
-
2018
- 2018-04-23 HR HRP20180641TT patent/HRP20180641T1/hr unknown
- 2018-05-23 CY CY20181100547T patent/CY1120340T1/el unknown
- 2018-12-06 US US16/211,848 patent/US10717725B2/en active Active
-
2020
- 2020-06-08 US US16/895,058 patent/US20200299267A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
MA39088B1 (fr) | Compositions et procédés pour moduler des récepteurs farnesoïde x | |
MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
EA201792515A1 (ru) | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОХИНОЛИНОНА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕТИНОИДНЫХ ОРФАНОВЫХ РЕЦЕПТОРОВ ГАММА (RORγ) | |
EA201791017A1 (ru) | Гидроксисодержащие соединения, модулирующие fxr (nr1h4) | |
MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
EA200901098A1 (ru) | Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов | |
MA40302A1 (fr) | Dérivés de carbazole | |
MX362383B (es) | Moduladores de acido oxabiciclo[2.2.2] gpr120. | |
EA201591815A1 (ru) | Бицикло [2.2.2] кислоты - модуляторы gpr120 | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
EA202091428A1 (ru) | Замещенные амиды ii пирролидина | |
EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
MX2015011375A (es) | Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1]. | |
MA39950B1 (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
EA202092146A1 (ru) | Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора | |
MX2016014118A (es) | Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes. | |
MA46965B1 (fr) | Modulateurs de gamma ror (rory) | |
MA43231B1 (fr) | Bloqueur des canaux sodiques | |
EA202091429A1 (ru) | Замещенные амиды i пирролидина | |
SA521431274B1 (ar) | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 |